Pierre Duvillard

Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial

Stephanie M. de Boer, Melanie Powell, Linda Mileshkin et al. · The Lancet Oncology · 2018 · 599 citations · Full text

Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin

Emmanuel Mitry, Éric Baudin, Michel Ducreux et al. · British Journal of Cancer · 1999 · 495 citations · Full text

Phase II Study of Cetuximab As First-Line Single-Drug Therapy in Patients With Unresectable Squamous Cell Carcinoma of the Skin

E. Maubec, Peter Petrow, Isabelle Scheer-Senyarich et al. · Journal of Clinical Oncology · 2011 · 456 citations · Full text

Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial

Stephanie M. de Boer, Melanie Powell, Linda Mileshkin et al. · The Lancet Oncology · 2019 · 432 citations · Full text

Detection of Liver Metastases From Endocrine Tumors: A Prospective Comparison of Somatostatin Receptor Scintigraphy, Computed Tomography, and Magnetic Resonance Imaging

Clarisse Dromain, Thierry de Baère, J. Lumbroso et al. · Journal of Clinical Oncology · 2004 · 383 citations · Full text